GO:1900239 regulation of phenotypic switching: Cellular Plasticity, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1900239 regulation of phenotypic switching describes any process that modulates the rate, frequency, or extent of phenotypic switching, the reversible or irreversible change of a cell from one phenotype to another [1, 2].
• Phenotypic switching is central to vascular smooth muscle cell (VSMC) plasticity in atherosclerosis, hypertension, and aortic aneurysm, where contractile VSMCs convert to synthetic, macrophage-like, or osteogenic phenotypes [1, 3, 4, 5, 6].
• The term also applies to non-mammalian systems, such as Photorhabdus luminescens, where phenotypic switching and heterogeneity are regulated in cell populations.
• Macrophage phenotypic switching (M1/M2 polarization) is a key regulatory node in inflammation and is targeted by drug delivery strategies.
• Cancer-associated fibroblasts (CAFs) can undergo phenotype switching toward a tumor-suppressive state upon YAP1 inhibition, demonstrating therapeutic tractability of this process.
• CRISPR-based knockout, knock-in, point mutation, and overexpression models are essential to dissect the causal regulators of phenotypic switching in disease [3, 8].
Description
Phenotypic switching is the process by which a cell changes from one phenotype to another, and its regulation (GO:1900239) encompasses any molecular event that modulates the rate, frequency, or extent of this transition [1, 2]. This biological process is fundamental to development, tissue repair, and disease, as it allows cells to adapt to changing microenvironments. In the vasculature, vascular smooth muscle cells (VSMCs) are a classic example: they switch from a contractile, quiescent phenotype to a synthetic, proliferative, and migratory phenotype in response to injury or atherogenic stimuli [1, 4, 5]. This plasticity is not limited to VSMCs; macrophages, cancer-associated fibroblasts (CAFs), and even bacterial populations exhibit regulated phenotypic switching [2, 7, 8]. The importance of GO:1900239 lies in its broad relevance to human disease. Dysregulated VSMC phenotypic switching contributes to atherosclerosis, hypertension, and aortic aneurysm/dissection [3, 4, 6]. Macrophage phenotypic switching between pro-inflammatory M1 and anti-inflammatory M2 states is a therapeutic target in inflammatory diseases. In cancer, CAF phenotype switching can either promote or suppress tumor growth, and its manipulation is an emerging therapeutic strategy. Understanding the regulators of phenotypic switching is therefore critical for developing targeted interventions. This article provides a research-grade overview of GO:1900239, integrating the QuickGO definition with verified PubMed literature. We cover the molecular and cellular mechanisms, key genes, disease associations, and state-of-the-art research methods, including CRISPR-based models. The content is designed for researchers seeking to study or manipulate phenotypic switching in cardiovascular disease, cancer, and beyond.
regulation of phenotypic switching At A Glance
| GO ID | GO:1900239 |
|---|---|
| GO term | regulation of phenotypic switching |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Modulates the rate, frequency, or extent of a cell's change from one phenotype to another |
| Definition source | QuickGO (no definition retrieved) |
| Related processes | Cell plasticity, differentiation, transdifferentiation, macrophage polarization, VSMC phenotype modulation |
| Disease relevance | Atherosclerosis, aortic aneurysm, hypertension, cancer, inflammatory diseases |
| Experimental approaches | CRISPR knockout/knock-in, lineage tracing, single-cell RNA-seq, proteomics |
What Is GO:1900239?
GO:1900239, regulation of phenotypic switching, is a biological process term that describes any process that modulates the frequency, rate, or extent of phenotypic switching. Phenotypic switching itself is the reversible or irreversible change of a cell from one phenotype to another, often in response to environmental cues or genetic reprogramming [1, 2]. The term does not specify the direction of the switch (e.g., contractile to synthetic or vice versa) but encompasses all regulatory inputs—transcriptional, epigenetic, post-transcriptional, and signaling—that control this transition. In practice, researchers study GO:1900239 by identifying genes and pathways that, when perturbed, alter the propensity of a cell to change its phenotype [3, 8].
Why Is regulation of phenotypic switching Important in Cell Biology?
GO:1900239 is important because phenotypic switching is a central mechanism of cellular adaptation and maladaptation in human disease. In cardiovascular disease, VSMC phenotypic switching drives plaque instability, aneurysm formation, and hypertension-related remodeling [1, 3, 4, 5, 6]. In cancer, CAF phenotype switching can determine whether the tumor microenvironment is pro- or anti-tumorigenic, and manipulating this switch via YAP1 inhibition has shown therapeutic potential. Macrophage phenotypic switching controls inflammation resolution and tissue repair, and its regulation is a target for drug delivery systems. Thus, understanding the regulators of phenotypic switching offers opportunities for diagnostic biomarkers and therapeutic intervention across multiple disease areas.
• VSMC phenotypic switching is a hallmark of atherosclerosis and contributes to plaque progression and instability [1, 5].
• Dysregulated VSMC switching is implicated in aortic aneurysm and dissection, with SLC44A2 identified as a key regulator.
• Hypertension and aortic dissection involve VSMC phenotype changes that affect vascular tone and wall integrity.
• Macrophage M1/M2 phenotypic switching is a therapeutic target in inflammatory diseases and is being exploited for drug delivery.
• CAF phenotype switching to a tumor-suppressive state can be induced by YAP1 inhibition, offering a novel cancer therapy strategy.
• Bacterial phenotypic switching, as in Photorhabdus luminescens, provides insights into population heterogeneity and adaptation.
• Regulation of phenotypic switching is essential for tissue regeneration and repair, and its dysregulation leads to fibrosis.
• Identifying regulators of phenotypic switching can reveal new drug targets and biomarkers for cardiovascular and oncological diseases [3, 8].
• CRISPR screens enable unbiased discovery of genes that regulate phenotypic switching, accelerating therapeutic development [3, 8].
• Single-cell technologies have revealed heterogeneity in phenotypic switching, underscoring the need for precise regulatory models [1, 2].
What Happens During regulation of phenotypic switching?
Initiation and Triggering Signals
In simple terms: Cells receive signals from their environment that tell them to change their identity.
Phenotypic switching is initiated by extracellular cues such as growth factors, cytokines, mechanical stress, or metabolic changes. In VSMCs, atherogenic lipids, angiotensin II, and inflammatory cytokines trigger the switch from a contractile to a synthetic phenotype [1, 4, 5]. In macrophages, toll-like receptor ligands and cytokines drive M1/M2 polarization. These signals activate intracellular signaling cascades, including MAPK, PI3K/AKT, and YAP/TAZ pathways, which converge on transcription factors that reprogram gene expression.
Transcriptional and Epigenetic Reprogramming
In simple terms: The cell rewrites its genetic instructions to adopt a new identity.
Upon triggering, master transcription factors such as MYOCD, SRF, KLF4, and NF-κB modulate the expression of contractile genes (e.g., ACTA2, MYH11) or inflammatory genes [1, 5]. Epigenetic modifiers, including histone acetyltransferases and DNA methyltransferases, alter chromatin accessibility at phenotype-specific loci. In CAFs, YAP1 inhibition leads to transcriptional reprogramming toward a tumor-suppressive state, highlighting the reversibility of these changes.
Phenotype Execution and Functional Changes
In simple terms: The cell physically and functionally becomes a different cell type.
The new transcriptional program leads to changes in cell morphology, proliferation, migration, and secretory profile. VSMCs switch from a spindle-shaped, contractile cell to a synthetic, migratory cell that produces extracellular matrix and inflammatory mediators [1, 6]. Macrophages shift their cytokine secretion and phagocytic capacity. CAFs alter their matrix remodeling and immune-modulatory functions. These functional changes are often accompanied by changes in cell surface markers, which can be used for sorting and analysis.
Feedback and Stabilization of the New Phenotype
In simple terms: The new identity is reinforced by feedback loops, making it stable until new signals arrive.
Once switched, the new phenotype can be stabilized by autocrine feedback loops and epigenetic memory. For example, synthetic VSMCs secrete factors that further promote inflammation and matrix degradation, perpetuating the switched state. In Photorhabdus luminescens, phenotypic switching and heterogeneity are regulated by a network of feedback loops that maintain population-level diversity. This stabilization can be reversed by targeting key regulators, such as SLC44A2 in VSMCs or YAP1 in CAFs [3, 8].
Key Genes Involved in GO:1900239 regulation of phenotypic switching
The following genes and proteins have been experimentally implicated in the regulation of phenotypic switching across cardiovascular, immune, and cancer contexts.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ACTA2 | Contractile VSMC marker; loss indicates synthetic switch | Assessing VSMC phenotype in atherosclerosis models [1, 5] |
| MYH11 | Contractile VSMC marker; downregulated during switching | Marker of contractile phenotype in vascular disease [4, 6] |
| KLF4 | Transcription factor promoting synthetic VSMC phenotype | Knockout reduces atherosclerosis in mice [1, 5] |
| MYOCD | Master regulator of contractile VSMC genes | Overexpression maintains contractile phenotype |
| SLC44A2 | Regulates VSMC phenotypic switching; involved in aortic aneurysm | Knockout/overexpression models in aortic aneurysm |
| YAP1 | Transcriptional co-activator; inhibition induces CAF phenotype switching | YAP1 inhibition as cancer therapy |
| NF-κB | Inflammatory transcription factor driving macrophage M1 polarization | Target for anti-inflammatory therapies |
| STAT6 | Transcription factor promoting M2 macrophage polarization | Modulating macrophage phenotype in inflammation |
| PPARG | Nuclear receptor promoting M2 phenotype | Agonists used to switch macrophages |
| TGFB1 | Cytokine inducing contractile VSMC phenotype and fibrosis | Context-dependent regulator of switching [4, 6] |
| PDGFB | Growth factor promoting synthetic VSMC phenotype | Used to induce phenotypic switching in vitro [1, 5] |
| IL-4 | Cytokine driving M2 macrophage polarization | In vitro macrophage switching assays |
| IFNG | Cytokine driving M1 macrophage polarization | In vitro macrophage switching assays |
| TNF | Pro-inflammatory cytokine promoting M1 and synthetic VSMC phenotypes | Inflammation models |
| MMP9 | Matrix metalloproteinase secreted by synthetic VSMCs | Marker of phenotypic switching in atherosclerosis [1, 6] |
| COL1A1 | Extracellular matrix component produced by synthetic VSMCs and CAFs | Fibrosis and tumor stroma models [5, 8] |
| CD68 | Macrophage marker; also expressed by macrophage-like VSMCs | Lineage tracing in atherosclerosis [1, 4] |
How Is regulation of phenotypic switching Regulated?
The regulation of phenotypic switching is mediated by a complex network of signaling pathways and transcription factors. Key pathways include the YAP/TAZ pathway, which controls CAF phenotype switching and can be inhibited to induce a tumor-suppressive state. In VSMCs, the MYOCD-SRF axis maintains the contractile phenotype, while KLF4 and NF-κB promote the synthetic phenotype [1, 5]. SLC44A2 has been identified as a critical regulator of VSMC phenotypic switching in aortic aneurysm, with its loss exacerbating the disease. Macrophage polarization is regulated by JAK-STAT, PI3K/AKT, and PPARγ pathways, which integrate cytokine signals to determine M1 versus M2 states. In Photorhabdus luminescens, phenotypic switching is controlled by a regulatory network involving feedback loops that generate population heterogeneity. These regulatory mechanisms are often context-dependent and can be targeted pharmacologically or genetically.
regulation of phenotypic switching and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC44A2 | Aortic aneurysm | VSMC-specific knockout mouse; overexpression in vitro |
| KLF4 | Atherosclerosis | ApoE-/- background with VSMC-specific KLF4 knockout [1, 5] |
| YAP1 | Prostate cancer | CAF-specific YAP1 knockout or pharmacological inhibition |
| PPARG | Inflammatory diseases | Macrophage-specific knockout; agonist treatment |
| ACTA2 | Vascular remodeling | Lineage tracing with ACTA2-CreERT2 [1, 4] |
Atherosclerosis and Cardiovascular Disease
VSMC phenotypic switching from a contractile to a synthetic, macrophage-like state is a hallmark of atherosclerosis. These switched cells contribute to plaque formation, fibrous cap stability, and inflammation [1, 5]. KLF4 and other transcription factors promote this switch, and their inhibition reduces lesion size in animal models. SLC44A2 regulates VSMC switching and is linked to aortic aneurysm, a related vascular pathology. Hypertension and aortic dissection also involve VSMC phenotype changes that compromise vascular integrity [4, 6].
Cancer and Tumor Microenvironment
Cancer-associated fibroblasts (CAFs) can undergo phenotype switching to either promote or suppress tumor growth. YAP1 inhibition induces a switch to a tumor-suppressive CAF phenotype in prostate cancer, demonstrating that this process is therapeutically targetable. Macrophage phenotypic switching in the tumor microenvironment also influences cancer progression, with M2-like macrophages generally promoting tumor growth. Thus, regulators of phenotypic switching are potential targets for cancer therapy.
Inflammatory and Immune Diseases
Macrophage phenotypic switching between pro-inflammatory M1 and anti-inflammatory M2 states is central to the resolution of inflammation. Dysregulated switching contributes to chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Therapeutic strategies that promote M2 polarization or inhibit M1 polarization are being developed, including drug delivery systems that target macrophages.
Bacterial Pathogenesis and Heterogeneity
In Photorhabdus luminescens, phenotypic switching generates population heterogeneity, which is important for adaptation to different hosts and environments. The regulation of this switching involves complex genetic networks and is a model for understanding cell fate decisions in bacteria. While not directly a human disease, this system provides insights into general principles of phenotypic regulation.
From regulation of phenotypic switching-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate VSMC phenotypic switching in atherosclerosis? | VSMC-specific knockout or overexpression in ApoE-/- mice [1, 3] |
| Can YAP1 inhibition switch CAFs to a tumor-suppressive phenotype? | CAF-specific YAP1 knockout or small molecule inhibitor in prostate cancer models |
| What is the role of SLC44A2 in aortic aneurysm? | SLC44A2 global or VSMC-specific knockout mouse |
| How does macrophage polarization affect inflammation resolution? | Macrophage-specific knockout of STAT6 or PPARG in colitis models |
| What are the transcriptional regulators of VSMC switching? | CRISPR screen in primary VSMCs followed by RNA-seq |
| Does point mutation in ACTA2 alter contractile phenotype? | Knock-in of ACTA2 mutations in induced pluripotent stem cells |
How to Study the regulation of phenotypic switching Process
| Method | What It Measures | Typical Application |
|---|---|---|
| scRNA-seq | Transcriptomes of individual cells | Identifying heterogeneous phenotypes in atherosclerosis [1, 4] |
| Lineage tracing | Cell fate and origin | Tracking VSMC-derived cells in plaques [1, 4] |
| CRISPR knockout screen | Gene function by loss-of-function | Discovering regulators of VSMC switching |
| Proteomics | Protein abundance and modifications | Validating expression changes during switching |
| Immunofluorescence | Protein localization and co-expression | Detecting macrophage-like VSMCs in tissue [1, 4] |
| Western blot | Protein expression levels | Confirming contractile marker loss in vitro |
| qRT-PCR | mRNA expression | Quantifying phenotype marker genes |
| Flow cytometry | Cell surface markers | Sorting M1/M2 macrophages |
Single-Cell RNA Sequencing
Single-cell RNA sequencing (scRNA-seq) allows unbiased identification of distinct cell phenotypes and their transitions within a tissue. In atherosclerosis, scRNA-seq has revealed multiple VSMC-derived cell states, including macrophage-like and osteogenic-like cells [1, 4]. This method is essential for studying heterogeneity in phenotypic switching and for discovering novel regulators.
Lineage Tracing and Genetic Fate Mapping
Lineage tracing using inducible Cre recombinase (e.g., ACTA2-CreERT2) enables tracking of VSMC fate during disease progression. This approach has demonstrated that a substantial fraction of plaque cells originate from VSMCs that underwent phenotypic switching [1, 4]. It is critical for establishing causality between a gene and phenotypic switching in vivo.
CRISPR Screens and Functional Genomics
Pooled CRISPR knockout screens can identify genes that regulate phenotypic switching. For example, a screen in VSMCs could use a contractile marker (e.g., ACTA2) as a readout to find regulators. Similarly, CRISPR activation or interference screens can modulate gene expression to uncover both positive and negative regulators [3, 8].
Proteomics and Phosphoproteomics
Mass spectrometry-based proteomics quantifies protein expression changes during phenotypic switching. Phosphoproteomics can reveal signaling pathways activated during the switch, such as YAP/TAZ or MAPK. These methods complement transcriptomic data and provide insight into post-transcriptional regulation.
How CRISPR Can Be Used to Study GO:1900239 regulation of phenotypic switching
Knockout
CRISPR knockout is used to delete candidate regulators of phenotypic switching and assess the consequences on cell phenotype. For example, knockout of SLC44A2 in VSMCs exacerbates aortic aneurysm, demonstrating its protective role. Knockout of KLF4 in VSMCs reduces atherosclerosis in mice. These models are essential for establishing causality.
Point Mutation
Point mutations can mimic human disease-associated variants or disrupt specific protein functions. For instance, introducing a point mutation in ACTA2 that impairs contractility can be used to study its effect on VSMC phenotypic switching. This approach is valuable for understanding how subtle genetic changes affect cell plasticity.
Knock-in
Knock-in of reporter genes (e.g., fluorescent proteins) or epitope tags allows real-time tracking of phenotype markers. A MYH11-GFP knock-in in VSMCs enables sorting of contractile versus synthetic cells. Knock-in of disease mutations (e.g., in SLC44A2) can model human aortic aneurysm.
Overexpression
Overexpression of a gene of interest can drive phenotypic switching. For example, overexpression of KLF4 in VSMCs promotes the synthetic phenotype. Overexpression of YAP1 in CAFs maintains a tumor-promoting state, while its inhibition induces a switch. These models help identify sufficiency of a gene in driving phenotype changes.
How EDITGENE Supports regulation of phenotypic switching Research
Researchers studying regulation of phenotypic switching-related genes often need to determine whether a candidate gene is causally involved in the transition from one cell phenotype to another. This requires precise genetic manipulation in relevant cell models, followed by functional readouts such as marker expression, proliferation, and migration. EDITGENE provides a comprehensive suite of CRISPR services to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for regulation of phenotypic switching research.
Frequently Asked Questions About regulation of phenotypic switching
What is GO:1900239 regulation of phenotypic switching?
GO:1900239 is a Gene Ontology biological process term that describes any process that modulates the rate, frequency, or extent of phenotypic switching, the change of a cell from one phenotype to another [1, 2].
What genes are involved in regulation of phenotypic switching?
Key genes include SLC44A2, KLF4, MYOCD, ACTA2, MYH11, YAP1, PPARG, STAT6, and NF-κB, among others, depending on the cell type and context [1, 3, 5, 7, 8].
How is phenotypic switching regulated in vascular smooth muscle cells?
VSMC phenotypic switching is regulated by transcription factors (e.g., KLF4, MYOCD), signaling pathways (e.g., YAP/TAZ, TGF-β), and epigenetic modifiers. SLC44A2 has been identified as a critical regulator in aortic aneurysm [1, 3, 5].
What diseases are associated with dysregulated phenotypic switching?
Dysregulated phenotypic switching is associated with atherosclerosis, aortic aneurysm, hypertension, cancer, and chronic inflammatory diseases [1, 3, 4, 5, 6, 7, 8].
Can CRISPR be used to study regulation of phenotypic switching?
Yes, CRISPR knockout, knock-in, point mutation, and overexpression models are widely used to dissect the causal role of specific genes in phenotypic switching [3, 8].
What is the role of YAP1 in phenotypic switching?
YAP1 inhibition induces a switch of cancer-associated fibroblasts to a tumor-suppressive phenotype in prostate cancer, demonstrating its regulatory role.
How does SLC44A2 regulate phenotypic switching?
SLC44A2 regulates vascular smooth muscle cell phenotypic switching, and its loss exacerbates aortic aneurysm in mouse models.
What methods are used to study phenotypic switching?
Common methods include single-cell RNA sequencing, lineage tracing, CRISPR screens, proteomics, and immunofluorescence [1, 4, 5, 8].
Is phenotypic switching reversible?
Phenotypic switching can be reversible or irreversible depending on the cell type and the stability of the new phenotype. For example, YAP1 inhibition can reverse CAF phenotype.
What is the difference between phenotypic switching and differentiation?
Phenotypic switching refers to a change in cell phenotype that can be reversible and often occurs in adult cells in response to environmental cues, whereas differentiation is typically a developmental process toward a specialized cell type [1, 2].
Conclusion
GO:1900239 regulation of phenotypic switching is a fundamental biological process with broad implications for cardiovascular disease, cancer, and inflammation. The integration of QuickGO annotation with verified literature highlights key regulators such as SLC44A2, KLF4, and YAP1, and demonstrates the power of CRISPR-based models to dissect these mechanisms. Understanding how phenotypic switching is controlled offers promising avenues for therapeutic intervention. EDITGENE provides the tools and expertise to accelerate this research, from knockout and knock-in models to high-throughput screens and bioinformatics.
References
- 1. Chen R et al.. 2023. Phenotypic Switching of Vascular Smooth Muscle Cells in Atherosclerosis.. J Am Heart Assoc 12(20):e031121 PMID: 37815057
- 2. Eckstein S et al.. 2019. Regulation of Phenotypic Switching and Heterogeneity in Photorhabdus luminescens Cell Populations.. J Mol Biol 431(23):4559-4568 PMID: 31022406
- 3. Song T et al.. 2024. SLC44A2 regulates vascular smooth muscle cell phenotypic switching and aortic aneurysm.. J Clin Invest 134(16) PMID: 38916960
- 4. Elmarasi M et al.. 2024. Phenotypic switching of vascular smooth muscle cells in atherosclerosis, hypertension, and aortic dissection.. J Cell Physiol 239(4):e31200 PMID: 38291732
- 5. Zhang F et al.. 2021. An update on the phenotypic switching of vascular smooth muscle cells in the pathogenesis of atherosclerosis.. Cell Mol Life Sci 79(1):6 PMID: 34936041
- 6. Tang HY et al.. 2022. Vascular Smooth Muscle Cells Phenotypic Switching in Cardiovascular Diseases.. Cells 11(24) PMID: 36552822
- 7. Wang X et al.. 2024. Macrophage-related therapeutic strategies: Regulation of phenotypic switching and construction of drug delivery systems.. Pharmacol Res 199:107022 PMID: 38043691
- 8. Song H et al.. 2024. YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer.. Cancer Res 84(22):3728-3742 PMID: 39137404
